SCHEDULE 13G/A: Wellington Management Group Discloses 4.3% Passive Stake in Alkermes PLC

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 4.3% beneficial ownership stake in Alkermes Public Limited Company as of December 31, 2024.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP are the reporting persons in this Schedule 13G Amendment No. 2.
• As of December 31, 2024, these entities collectively beneficially own 7,012,483 shares of Alkermes Public Limited Company's Common Stock.
• This beneficial ownership represents 4.3% of the total class of Alkermes Public Limited Company's Common Stock.
• The reporting persons hold shared voting power over 6,838,679 shares and shared dispositive power over 7,012,483 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Alkermes Public Limited Company.

Sentiment

Score: 5

Explanation: The document is a routine Schedule 13G filing disclosing beneficial ownership, which is neutral in sentiment regarding the issuer's operational performance or future prospects. It primarily conveys information about an institutional investor's passive stake.

Positives

• The filing confirms that Wellington Management Group LLP and its affiliates maintain a significant, albeit passive, investment in Alkermes Public Limited Company, reflecting continued institutional interest.
• The certification that the securities are held in the ordinary course of business and not for control purposes provides clarity on the investor's intent, suggesting stability in the ownership structure.

Negatives

• The document, a Schedule 13G, does not contain information regarding the operational or financial negatives of Alkermes Public Limited Company.

Risks

• The document, a Schedule 13G, does not contain information regarding specific risks related to Alkermes Public Limited Company's operations or financial health.

Future Outlook

The Schedule 13G filing does not provide any forward-looking statements or guidance regarding Alkermes Public Limited Company's future outlook.

Management Comments

• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates continued institutional investor interest in the pharmaceutical and biotechnology sector, with a significant asset manager like Wellington Management Group maintaining a substantial stake in Alkermes Public Limited Company.

Comparison to Industry Standards

• The Schedule 13G filing does not provide information for comparison to industry standards or specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception.
• Management: Awareness of a large, passive institutional holder.

Next Steps

• The reporting persons will file amendments to this Schedule 13G if there are material changes to their beneficial ownership or intent.

Key Dates

Keywords

Alkermes Public Limited Company, Wellington Management Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Pharmaceutical, Biotechnology